A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease
Kidney International · 2023-05 · 103 (5) · 917-929
DOI: 10.1016/j.kint.2023.01.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2023-05. Verfasst von Pascale Gluais Dagorn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Poxel SA, Lyon, France. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant, Renal Insufficiency, Cysts. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Autosomal dominant polycystic kidney disease (ADPKD) mainly results from mutations in the PKD1 gene, which encodes polycystin 1. It is the most common inherited kidney disease and is characterized by a progressive bilateral increase in cyst number and size, often leading to kidney failure. The cellular energy sensor and regulator adenosine monophosphate stimulated protein kinase (AMPK) has been implicated as a promising new therapeutic target. To address this hypothesis, we determined the effects of a potent and selective clinical stage direct allosteric AMPK activator, PXL770, in canine and patient-derived 3D cyst models and an orthologous mouse model of ADPKD. PXL770 induced AMPK activation and dose-dependently reduced cyst growth in principal-like Madin-Darby Canine Kidney cells stimulated with forskolin and kidney epithelial cells derived from patients with ADPKD stimulated with desmopressin. In an inducible, kidney epithelium-specific Pkd1 knockout mouse model, PXL770 produced kidney AMPK pathway engagement, prevented the onset of kidney failure (reducing blood urea by 47%), decreased cystic index by 26% and lowered the kidney weight to body weight ratio by 35% compared to untreated control Pkd1 knockout mice. These effects were accompanied by a reduction of markers of cell proliferation (-48%), macrophage infiltration (-53%) and tissue fibrosis (-37%). Thus, our results show the potential of direct allosteric AMPK activation in the treatment of ADPKD and support the further development of PXL770 for this indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Poxel SA, Lyon, France.
- Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
- Crown Bioscience Netherlands B.V., The Netherlands.
- InnoSer België NV, Belgium.
- Poxel SA, Lyon, France. Electronic address: sophie.bozec@poxelpharma.com.
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Dagorn, P. G., Buchholz, B., Kraus, A., Batchuluun, B., Bange, H., Blockken, L., Steinberg, G. R., Moller, D. E., & Hallakou-Bozec, S. (2023). A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease. Kidney International, 103(5), 917-929. https://doi.org/10.1016/j.kint.2023.01.026
Vancouver
Dagorn PG, Buchholz B, Kraus A, Batchuluun B, Bange H, Blockken L, et al. A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease. Kidney International. 2023;103(5):917-929. doi:10.1016/j.kint.2023.01.026
BibTeX
@article{Dagorn2023,
author = {Dagorn, Pascale Gluais and Buchholz, Bjoern and Kraus, Andre and Batchuluun, Battsetseg and Bange, Hester and Blockken, Laura and Steinberg, Gregory R and Moller, David E and Hallakou-Bozec, Sophie},
title = {A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease},
journal = {Kidney International},
year = {2023},
volume = {103},
number = {5},
pages = {917--929},
doi = {10.1016/j.kint.2023.01.026}
}
EUVIMED